Accutar Biotechnology Receives NMPA Clearance of IND Application for AC0682 in ER-Positive Breast Cancer

Accutar Biotechnology Receives NMPA Clearance of IND Application for AC0682 in ER-Positive Breast Cancer

BROOKLYN, N.Y. & SHANGHAI–(BUSINESS WIRE/AETOSWire)– Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, announces that the China National Medical Products Administration (NMPA) has cleared the company’s investigational new drug application (IND) for AC0682 for the treatment of patients with estrogen receptor (ER)-positive breast cancers. AC0682 is an orally bioavailable chimeric degrader molecule designed to target ERα protein with high potency and selectivity. “Breast cancer is the most common cancer among women in China. We are excited about the IND clearance of AC0682 in…

DA’s February Report Says Concerns Around Taxation were Short-Lived as UAE Consumer Confidence Remains Net Positive

DA’s February Report Says Concerns Around Taxation were Short-Lived as UAE Consumer Confidence Remains Net Positive

Dubai, United Arab Emirates Consumer confidence in the UAE dipped to 70.9% in February, however, it is expected to rebound quickly because of long-term consumer optimism surrounding the country’s economy Short-term negativity during February, a result of the private company income tax announcement, was quickly replaced as the news cycle moved on with early indicators predicting a return to growth The GCC rebounded well to see net consumer confidence increase 0.7% in February to 58.1% The February report, produced and developed by D/A, utilises AI technology to measure consumer confidence amongst…